Cumulative Incidence Curves of Time to Progression to the Next Development Phase by Time Elapsed After Trial Start for Cardiovascular Drugs Compared With Noncardiovascular Drugs in Phase 1, 2, and 3 Trials
Cumulative incidence curves of progression to the next development phase for cardiovascular (Anatomical Therapeutic Chemical [ATC] codes B and C; shown in blue) and noncardiovascular (shown in grey) drugs in Phase 1 (A), Phase 2 (B), and Phase 3 (C) trials.